C3657

Sigma-Aldrich

Collagen from human placenta

Bornstein and Traub Type V (Sigma Type IX), powder

CAS Number:
EC Number:
MDL number:
NACRES:
NA.32
Pricing and availability is not currently available.

biological source

human placenta

form

powder

application(s)

detection: suitable

impurities

HIV, hepatitis B and hepatitis C, none detected

solubility

aqueous acid: soluble

storage temp.

2-8°C

Gene Information

human ... COL5A1(1289)

Looking for similar products? Visit Product Comparison Guide

Packaging

1, 5 mg in glass bottle

Components

All collagen molecules are composed of three polypeptide chains arranged in a triple helical conformation, with a primary structure that is mostly a repeating motif with glycine in every third position and proline or 4-hydroxyproline frequently preceding the glycine residue.

Caution

This product should be stored desiccated at -20°C, and will retain activity in these conditions for 3 years.

Preparation Note

This product was prepared by a modification of the pepsin extraction and salt fractionation method of Niyibizi, C., et al., J. Biol. Chem., 259, 14170 (1984). It is an acid soluble collagen that can be dissolved in water with acetic acid added to pH 3.0 (5 mg/mL), yielding an opalescent, colorless solution.

Analysis Note

An SDS polyacrylamide gel electrophoresis test run under reducing conditions consistent with basement membrane collagen yields three major bands.

Other Notes

Collagen is classified into a number of structurally and genetically distinct types. We use the nomenclature proposed by Bornstein and Traub. Be wary of confusing Sigma-type designations with recognized collagen classification types.

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Caroline Forsell et al.
The Annals of thoracic surgery, 98(1), 65-71 (2014-06-03)
The prevalence for thoracic aortic aneurysms (TAAs) is significantly increased in patients with a bicuspid aortic valve (BAV) compared with patients who have a normal tricuspid aortic valve (TAV). TAA rupture is a life-threatening event, and biomechanics-based simulations of the...
Pietro Felice et al.
European journal of oral implantology, 7(1), 65-75 (2014-06-04)
To compare the efficacy of 1-stage versus 2-stage lateral maxillary sinus lift procedures. Sixty partially edentulous patients requiring 1 to 3 implants and having 1 to 3 mm of residual bone height and at least 5 mm bone width below...
Maurits L van Montfoort et al.
Arteriosclerosis, thrombosis, and vascular biology, 34(8), 1668-1673 (2014-06-21)
Coagulation factor XI is proposed as therapeutic target for anticoagulation. However, it is still unclear whether the antithrombotic properties of factor XI inhibitors influence atherosclerotic disease and atherothrombosis. Our aim is to investigate whether factor XI antisense oligonucleotides could prevent...
Marco Esposito et al.
European journal of oral implantology, 6(2), 169-179 (2013-08-09)
To compare the clinical effectiveness of two implant systems: Way Milano and Kentron (Geass, Pozzuolo del Friuli, UD, Italy). A total of 64 patients requiring at least two single crowns or partial fixed dental prostheses supported by a maximum of...
Pietro Felice et al.
European journal of oral implantology, 6(2), 153-165 (2013-08-09)
To compare the efficacy of 1-stage versus 2-stage lateral maxillary sinus lift procedures. Sixty partially edentulous patients requiring 1 to 3 implants and having 1 to 3 mm of residual bone height and at least 5 mm of bone width...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.